Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.

Blazevski A, Scheltema MJ, Amin A, Thompson JE, Lawrentschuk N, Stricker PD.

BJU Int. 2019 Nov 14. doi: 10.1111/bju.14951. [Epub ahead of print] Review.

PMID:
31725935
2.

Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.

Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W, Shnier R, Haynes AM, Cusick T, Thompson J, Stricker P.

Eur Urol Oncol. 2019 May 16. pii: S2588-9311(19)30057-4. doi: 10.1016/j.euo.2019.04.008. [Epub ahead of print]

PMID:
31103721
3.

Irreversible Electroporation for the Ablation of Prostate Cancer.

Karagiannis A, Varkarakis J.

Curr Urol Rep. 2019 Sep 2;20(10):63. doi: 10.1007/s11934-019-0929-x. Review.

PMID:
31478109
4.

Focal irreversible electroporation as primary treatment for localized prostate cancer.

van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2018 May;121(5):716-724. doi: 10.1111/bju.13983. Epub 2017 Sep 4.

5.

A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Valerio M, Dickinson L, Ali A, Ramachandran N, Donaldson I, Freeman A, Ahmed HU, Emberton M.

Contemp Clin Trials. 2014 Sep;39(1):57-65. doi: 10.1016/j.cct.2014.07.006. Epub 2014 Jul 26.

6.

Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.

Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19.

7.

Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.

Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, Stehling MK.

PLoS One. 2019 Apr 15;14(4):e0215093. doi: 10.1371/journal.pone.0215093. eCollection 2019.

8.

Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.

Scheltema MJ, van den Bos W, de Bruin DM, Wijkstra H, Laguna MP, de Reijke TM, de la Rosette JJ.

BMC Cancer. 2016 May 5;16:299. doi: 10.1186/s12885-016-2332-z.

9.

The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.

van den Bos W, de Bruin DM, Muller BG, Varkarakis IM, Karagiannis AA, Zondervan PJ, Laguna Pes MP, Veelo DP, Savci Heijink CD, Engelbrecht MRW, Wijkstra H, de Reijke TM, de la Rosette JJMCH.

BMJ Open. 2014 Oct 29;4(10):e006382. doi: 10.1136/bmjopen-2014-006382.

10.

Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy.

Scheltema MJ, Chang JI, Böhm M, van den Bos W, Blazevski A, Gielchinsky I, Kalsbeek AMF, van Leeuwen PJ, Nguyen TV, de Reijke TM, Siriwardana AR, Thompson JE, de la Rosette JJ, Stricker PD.

World J Urol. 2018 Sep;36(9):1383-1389. doi: 10.1007/s00345-018-2281-z. Epub 2018 Mar 28.

11.

A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).

Wendler JJ, Porsch M, Nitschke S, Köllermann J, Siedentopf S, Pech M, Fischbach F, Ricke J, Schostak M, Liehr UB.

Contemp Clin Trials. 2015 Jul;43:10-9. doi: 10.1016/j.cct.2015.05.002. Epub 2015 May 9.

PMID:
25962890
12.

[Irreversible electroporation. Current value for focal treatment of prostate cancer].

Wendler JJ, Ganzer R, Hadaschik B, Blana A, Henkel T, Köhrmann KU, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D, Köllermann J, Schostak M, Liehr UB; Working Group for Focal and Microtherapy, Academy of the German Society of Urology.

Urologe A. 2015 Jun;54(6):854-62. doi: 10.1007/s00120-015-3864-6. Review. German.

PMID:
26024649
13.

Focal Therapy of Prostate Cancer Using Irreversible Electroporation.

Valerio M, Ahmed HU, Emberton M.

Tech Vasc Interv Radiol. 2015 Sep;18(3):147-52. doi: 10.1053/j.tvir.2015.06.005. Epub 2015 Jun 18. Review.

PMID:
26365544
14.

Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.

Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):46-52. doi: 10.1038/pcan.2015.47. Epub 2015 Oct 13.

PMID:
26458959
15.

Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.

Beyer LP, Pregler B, Nießen C, Michalik K, Haimerl M, Stroszczynski C, Jung EM, Wiggermann P.

Clin Hemorheol Microcirc. 2016;64(3):501-506. doi: 10.3233/CH-168125.

PMID:
27935553
16.

Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer.

Moris D, Machairas N, Tsilimigras DI, Prodromidou A, Ejaz A, Weiss M, Hasemaki N, Felekouras E, Pawlik TM.

Ann Surg Oncol. 2019 Jun;26(6):1657-1668. doi: 10.1245/s10434-019-07261-7. Epub 2019 Mar 6.

PMID:
30843163
17.

New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M.

Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29. Review.

PMID:
27595377
18.

Irreversible Electroporation for the Ablation of Renal Cell Carcinoma: A Prospective, Human, In Vivo Study Protocol (IDEAL Phase 2b).

Buijs M, van Lienden KP, Wagstaff PG, Scheltema MJ, de Bruin DM, Zondervan PJ, van Delden OM, van Leeuwen TG, de la Rosette JJ, Laguna MP.

JMIR Res Protoc. 2017 Feb 16;6(2):e21. doi: 10.2196/resprot.6725.

19.

Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.

Murray KS, Ehdaie B, Musser J, Mashni J, Srimathveeravalli G, Durack JC, Solomon SB, Coleman JA.

J Urol. 2016 Sep;196(3):883-90. doi: 10.1016/j.juro.2016.02.2986. Epub 2016 Apr 23.

20.

MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.

van den Bos W, de Bruin DM, van Randen A, Engelbrecht MR, Postema AW, Muller BG, Varkarakis IM, Skolarikos A, Savci-Heijink CD, Jurhill RR, Zondervan PJ, Laguna Pes MP, Wijkstra H, de Reijke TM, de la Rosette JJ.

Eur Radiol. 2016 Jul;26(7):2252-60. doi: 10.1007/s00330-015-4042-3. Epub 2015 Oct 8.

Supplemental Content

Support Center